Jun Ma, M.D.
Sun Yat-sen University
10
7
1
N/A
0
8
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+6 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (10)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Xiaozhong Chen, MD
Zhejiang Cancer Hospital
Shared therapeutic areas:
Allan Hildesheim, Ph.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Weijun Wei, Ph.D. & M.D.
Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
Shared therapeutic areas:
li zhang, doctor
Sun Yat-sen University
Shared therapeutic areas:
Worked with same sponsors:
Ming-yuan Chen, MD, PhD
Sun Yat-sen University
Shared therapeutic areas:
Worked with same sponsors:
Nancy Lee, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Ming-Yuan Chen, MD,PhD
Sun Yat-sen University
Shared therapeutic areas:
Worked with same sponsors:
Lizhi Niu, PhD
Fuda Cancer Hospital
Shared therapeutic areas:
Han-Kuei Wu, Ph.D.
China Medical University, China
Shared therapeutic areas:
Kun San Chao, M.D.
China Medical University, China
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (10)
Showing 10 of 10 trials
LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma
Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)
PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma
Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma
To Study the Feasibility and Quality of Life of Medial Group Retropharyngeal Node Sparing in Nasopharyngeal Carcinoma
Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated Radiotherapy
ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma
All 10 trials loaded